Source comparison
CJC-1295 no DAC & Ipamorelin Contraindications: Peptide Comparison
The following table compares contraindication profiles across commonly stacked growth hormone secretagogues. Understanding these differences helps researchers select peptides with the lowest risk profile for specific medical histories. CJC-1295 no DAC GHRH ana
This comparison does not assign a generated winner or score.
- The following table compares contraindication profiles across commonly stacked growth hormone secretagogues. Understanding these differences helps researchers select peptides with the lowest risk profile for specific medical histories.
- CJC-1295 no DAC
- GHRH analogue, pituitary GH release
- Active cancer, pregnancy, Class III-IV heart failure
- Diabetes, thyroid disease, renal insufficiency
- Moderate. Affects insulin sensitivity, thyroid conversion
- Best for patients without metabolic comorbidities; requires glucose monitoring in diabetics
- Ipamorelin
- Ghrelin mimetic, GH pulse generation
- Active cancer, pregnancy, severe cardiac disease
- Diabetes, documented arrhythmias, CKD Stage 3+
- Low-moderate. Minimal cortisol/prolactin elevation, cleaner profile
- Cleanest side effect profile; preferred first choice for patients with borderline contraindications
- CJC-1295 with DAC
- Long-acting GHRH analogue
- Same as no DAC, plus hepatic impairment
- Same as no DAC, with extended washout concerns
- High. Prolonged elevation increases cumulative exposure risk
- Extended half-life (8–10 days) makes adverse events harder to manage; avoid in patients with multiple comorbidities
- Sermorelin
- Short-acting GHRH analogue
- Active cancer, pregnancy
- Diabetes, thyroid disease
- Low. Short half-life limits cumulative effects
- Lower potency but safer profile for patients requiring titration or with metabolic concerns
- Tesamorelin
- GHRH analogue, visceral fat targeting
- Active cancer, pregnancy, diabetic retinopathy
- Diabetes, especially poor glycemic control
- Moderate-high. Specifically worsens glucose control, approved only for HIV lipodystrophy
- Narrowest therapeutic use case; contraindicated in most diabetes patients
- This comparison demonstrates that Ipamorelin has the most favorable contraindication profile among growth hormone secretagogues, while CJC-1295 with DAC presents the highest risk due to prolonged exposure. The CJC1295 Ipamorelin 5MG 5MG blend combines complementary mechanisms while maintaining a manageable risk profile. But only when contraindications are properly screened before use.